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Background. Quantifying the amount and diversity of antibiotic use in United States hospitals assists antibiotic stewardship efforts but is hampered by limited national surveillance. Our study aimed to address this knowledge gap by examining adult antibiotic
use across 576 hospitals and nearly 12 million encounters in 2016–2017.
Methods. We conducted a retrospective study of patients aged ≥ 18 years discharged from hospitals in the Premier Healthcare
Database between 1 January 2016 and 31 December 2017. Using daily antibiotic charge data, we mapped antibiotics to mutually exclusive classes and to spectrum of activity categories. We evaluated relationships between facility and case-mix characteristics and
antibiotic use in negative binomial regression models.
Results. The study included 11 701 326 admissions, totaling 64 064 632 patient-days, across 576 hospitals. Overall, patients
received antibiotics in 65% of hospitalizations, at a crude rate of 870 days of therapy (DOT) per 1000 patient-days. By class, use
was highest among β-lactam/β-lactamase inhibitor combinations, third- and fourth-generation cephalosporins, and glycopeptides.
Teaching hospitals averaged lower rates of total antibiotic use than nonteaching hospitals (834 vs 957 DOT per 1000 patient-days;
P < .001). In adjusted models, teaching hospitals remained associated with lower use of third- and fourth-generation cephalosporins
and antipseudomonal agents (adjusted incidence rate ratio [95% confidence interval], 0.92 [.86–.97] and 0.91 [.85–.98], respectively). Significant regional differences in total and class-specific antibiotic use also persisted in adjusted models.
Conclusions. Adult inpatient antibiotic use remains high, driven predominantly by broad-spectrum agents. Better understanding reasons for interhospital usage differences, including by region and teaching status, may inform efforts to reduce inappropriate antibiotic prescribing.
Keywords. antibiotic stewardship; antimicrobial use; surveillance; inpatient.
Antibiotic stewardship—prescribing antibiotics only when
clinically appropriate, for the right amount of time, and with
the right drug—is a critical tool for fighting antibiotic resistance in inpatient settings [1]. Understanding the volume and
types of antibiotics used across United States (US) hospitals is
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an integral component of antibiotic stewardship efforts. These
national data can reveal large-scale prescribing trends, as well as
significant geographic or facility-level prescribing differences,
that remain obscured with local or institution-specific data.
They can also identify potential policy targets and provide historical benchmarks for evaluating longitudinal trends.
Limited national surveillance makes quantifying inpatient
antibiotic use challenging. Academic studies have filled this informational void, and in recent years a number of important
studies have examined US inpatient antibiotic prescribing [2–5].
Our research continues these efforts by presenting updated data
captured from a larger number of hospitals in more granular detail than previous work. The objective of the current study is to
provide a comprehensive examination of adult inpatient antibiotic usage, including its association with different geographic, facility, and case-mix characteristics, across 576 US hospitals and
nearly 12 million adult encounters in 2016–2017.
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METHODS
Study Setting and Population

Adult inpatient encounters and associated data were collected
from hospitals in the Premier Healthcare Database (“Premier
Database”). The Premier Database is an all-payer repository
of claims and clinical data from > 870 million inpatient and
outpatient US hospital encounters, across > 800 hospitals. It
includes approximately 1 of every 4 annual inpatient admissions [6] (Supplementary Data). All adult encounters (age
≥ 18 years at admission) with discharge dates on or between
1 January 2016 and 31 December 2017 at hospitals that continuously submitted data during the 24-month study period
were included. This study did not include personally identifiable information and was exempt from institutional review
board review.
Collected Data

The Premier Database contains comprehensive facility and
demographic information, as well as a date-stamped log of all
billed therapeutic services and medications. For each admission,
we extracted the following data from the Premier Database: (1)
facility data (eg, US census geographic division [7], bed size,
teaching status); (2) patient sociodemographic data; and (3)
patient clinical data, including intensive care unit (ICU) days,
and all International Classification of Diseases, Tenth Revision
(ICD-10) diagnosis codes and the Medicare Severity DiagnosisRelated Group (MS-DRG) code associated with each encounter.
Using MS-DRG codes, we calculated each hospital’s case-mix
index, a weighting schema used by the Centers for Medicare
and Medicaid Services (CMS) to adjust for resource intensity [8–10]. We mapped ICD-10 diagnosis codes to Elixhauser
comorbidities using Agency for Healthcare Research and
Quality (AHRQ) software [11]. Elixhauser comorbidities were
summed to create an unweighted Elixhauser score. The Premier
Database does not contain microbiology data; therefore, we
used AHRQ bacterial infection diagnosis codes to ascertain
whether a patient’s primary ICD-10 diagnosis was infectionrelated [12]. Inpatient days for encounters with a primary infection diagnosis were treated as “bacterial infection” patient-days
(PD). To measure antibiotic utilization, we obtained daily antibiotic charge data for each encounter, including drug name(s),
route(s) of administration, and service-day unit location.
Antibiotic Class and Spectrum of Activity Classifications

To design study outcomes, we surveyed the literature to
identify commonly reported antibiotic classes [2–4, 13].
Two infectious disease physicians (A. D. H. and S. E. C.)
reviewed the results and proposed additional antibiotic
classes and spectrum of activity categories based upon
clinical relevance. Where in joint agreement, these outcomes were also included. All decisions were completed
prior to data analysis, and based upon final consensus, we
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mapped each antibiotic to 1 of 18 mutually exclusive antibiotic classes: aminoglycosides; β-lactam/β-lactamase
inhibitor combinations; β-lactam/β-lactamase inhibitor
combinations for multidrug-resistant gram-negative organisms; carbapenems; first- and second-generation cephalosporins; fluoroquinolones; glycopeptides; lincosamides;
macrolides; metronidazole; monobactams; oxazolidinones;
penicillins; polymyxins; sulfonamides; tetracyclines; thirdand fourth-generation cephalosporins; and other antibacterial agents (Supplementary Appendix A). In addition, we
mapped antibiotics to non–mutually exclusive categories
based upon activity against Bacteroides fragilis, Pseudomonas
species, methicillin-resistant Staphylococcus aureus (MRSA),
and Clostridioides difficile (Supplementary Appendix A).
Statistical Methods

Descriptive statistics for patient and hospital characteristics were
calculated using mean (standard deviation [SD]), median (range
or interquartile range [IQR]), or frequency count (percentage).
Consistent with other studies and Centers for Disease Control
and Prevention (CDC) National Healthcare Safety Network
(NHSN) antimicrobial use surveillance, we used total inpatient
days of therapy (DOT) as the primary study outcome [2, 3, 14,
15]. For each admission, DOT sums were calculated for total antibiotic use, and separately for each antibiotic class and spectrum
of activity category. If a patient received 2 different antibiotics on
the same service day, these events qualified as 2 DOT [2, 14, 15].
To provide standardized summary measures, values were aggregated across the cohort and reported as rates per 1000 PD and
as dichotomized outcomes (percentage of encounters with antibiotic use, yes/no). To facilitate comparisons with prior studies,
we also calculated hospital mean total usage rates (rather than
a single crude rate across all facilities), and rates stratified by
teaching status and patient age.
For statistical models, patient-level characteristics were
transformed into hospital-level case-mix variables (eg, hospital mean patient age) and DOT and PD were summed for
each hospital. Relationships between DOT and hospital,
case-mix, and geographic variables were evaluated at the
facility level in univariable negative binomial regression
models. We used an offset equal to the natural log of PD per
hospital and summarized results with incidence rate ratios
(IRRs) and 95% confidence intervals (CIs). Variables with
P values < .10 were evaluated in multivariable negative binomial models; biologically plausible interaction terms were
retained if at least 1 strata’s P value was < .10 and at least 1
other strata’s P value was ≥ .10, or if effect estimates across
strata differed by > 10% in models including only the main
and interaction effects. All tests were 2-tailed, and P values
≤ .05 were used for statistical significance testing. Analyses
were performed using SAS version 9.4 (SAS Institute) and
Stata 15.0 (StataCorp).

Table 1. Description of Facility, Case-mix, and Geographic Characteristics
Among Adult Inpatient Encounters in the Premier Healthcare Database,
United States, 2016–2017
Characteristic
Total No. of encounters

Hospitals (N = 576)
11 701 326

No. of encounters by year
2016

5 834 810

2017

5 866 516

Total patient-days

64 064 632

Facility fixed characteristics
Urbana

432 (75)

Teaching

170 (30)

Bed size
0–99

126 (22)

100–199

143 (25)

200–299

102 (18)

300–399

82 (14)

400–499

41 (7)

≥ 500

82 (14)

Facility case-mix characteristics
Patient-days, median (IQR)
Average patient age, y,
median (IQR)
Percentage of patient-days
in ICUs, median (IQR)

80 318 (33 301–157 535)
59 (57–63)
11 (6–14)

Percentage of bacterial infection
patient-days, median (IQR)b

24 (21–27)

Average Elixhauser comorbidity
index score, mean (SD)c

3.2 (0.59)

Case-mix index, median (IQR)

1.46 (1.32–1.64)

Facility geographical characteristics
US census region and divisiond
  Northeast
Mid-Atlantic

63 (11)

New England

13 (2)

  South
East South Central

37 (6)

West South Central

62 (11)

South Atlantic

161 (28)

  Midwest
West North Central

46 (8)

East North Central

101 (18)

  West
Mountain

25 (4)

Pacific

68 (12)

Data are presented as no. (%) unless otherwise indicated. Percentages for mutually exclusive subcategories may exceed 100% due to rounding.
Abbreviations: ICU, intensive care unit; IQR, interquartile range; SD, standard deviation;
US, United States.
a

Designation provided by Premier, based upon American Hospital Association Annual
Survey response.
b
Agency for Healthcare Research and Quality (AHRQ) infection diagnosis codes were used
to ascertain whether a patient’s primary International Classification of Diseases, Tenth
Revision diagnosis was infection-related (AHRQ, 2019). Inpatient-days for encounters with
a primary infection diagnosis were treated as “bacterial infection” patient-days.
c
Elixhauser comorbidity classifications were modified to include primary diagnoses, in addition to secondary diagnoses. Patient Elixhauser scores were calculated as an unweighted
sum (1 point per comorbidity), and average scores were calculated for each facility.
d
US census divisions comprise 4 US census regions: Northeast (Middle Atlantic, New
England); South (South Atlantic, East South Central, West South Central); Midwest (East
North Central, West North Central); and West (Mountain, Pacific). States in each US census
division are as follows: New England Division: Connecticut, Maine, Massachusetts, New
Hampshire, Rhode Island, Vermont; Middle Atlantic Division: New Jersey, New York,
Pennsylvania; East North Central Division: Illinois, Indiana, Michigan, Ohio, Wisconsin; West

RESULTS

During the 2-year study period spanning calendar years 2016
and 2017, there were 11 701 326 unique adult inpatient encounters, totaling 64 064 632 PD, across 576 US hospitals
(Supplementary Figure 1). Hospital and patient characteristics
are presented in Table 1 and Supplementary Table 1. Twentyeight percent (28%) of hospitals were located in the South
Atlantic US census division, followed by the East North Central
(18%) and the Pacific (12%). Seventy-five percent (75%) of
hospitals were urban, and 30% had academic teaching status
(Table 1). Patients had a median age of 62 (IQR, 42–75) years,
59% were female, and the median length of hospital stay was 4
(IQR, 3–6) service days (Supplementary Table 1).
Antibiotic Usage

Overall, 65% of patients received at least 1 antibiotic while hospitalized (Table 2). The crude rate of total antibiotic use across
all encounters was 870 DOT per 1000 PD. By antibiotic class,
β-lactam/β-lactamase inhibitor combinations had the highest
usage rate (206 DOT/1000 PD), driven predominantly by
piperacillin-tazobactam administration (Figure 1). The remaining top 5 antibiotic classes by usage rate were third- and
fourth-generation cephalosporins (128 DOT/1000 PD; 98% parenteral), glycopeptides (113 DOT/1000 PD; 99% of use attributable to vancomycin), first- and second-generation cephalosporins
(81 DOT/1000 PD; 90% parenteral), and fluoroquinolones (75
DOT/1000 PD; 66% parenteral) (Figure 1 and Table 2). When
dichotomizing use as present or absent per encounter, these antibiotic classes remained the most common, but their rankings
changed (eg, first- and second-generation cephalosporins became
the most common, used in 24% of all encounters) (Table 2).
We also categorized and measured antibiotic use by spectrum of activity. Agents with antipseudomonal activity had the
highest usage (245 DOT/1000 PD and used in 29% of encounters), followed by agents active against B. fragilis (220 DOT/1000
PD and used in 25% of encounters), MRSA (161 DOT/1000 PD
and used in 24% of encounters), and C. difficile (23 DOT/1000
PD and used in 3% of encounters) (Table 2).
Additional Metrics of Total Antibiotic Use to Facilitate Cross-study
Comparisons

Stratifying by patient age, within categories of 18–44, 45–64,
65–84, and ≥ 85 years, rates of total antibiotic use were 682,
943, 913, and 889 DOT per 1000 PD, respectively. The hospital mean rate of total antibiotic use was 921 DOT/1000 PD
(SD, 208). Stratifying by teaching status, the mean rate of total

North Central Division: Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South
Dakota; South Atlantic Division: Delaware, District of Columbia, Florida, Georgia, Maryland,
North Carolina, South Carolina, Virginia, West Virginia; East South Central Division: Alabama,
Kentucky, Mississippi, Tennessee; West South Central Division: Arkansas, Louisiana,
Oklahoma, Texas; Mountain Division: Arizona, Colorado, Idaho, Montana, Nevada, New
Mexico, Utah, Wyoming; Pacific Division: Alaska, California, Hawaii, Oregon, Washington.
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Table 2.

Antibiotic Use Across 11 701 326 Adult Inpatient Encounters, United States, 2016–2017

Antibiotic

DOT per 1000 PD

Percentage of Encounters With ≥ 1 DOT (N = 11 701 326)

869.5

64.9

Antibiotic class
All (total)
Aminoglycosides
β-lactam/β-lactamase inhibitor combinations
β-lactam/β-lactamase inhibitor combinations for MDRGNs

9.8

3.1

206.4

14.5

0.5

0.03

Carbapenems

57.8

3.9

First- and second-generation cephalosporins

80.5

23.6

Fluoroquinolones

75.1

13.3

Glycopeptides

113.3

19.2

Lincosamides

38.0

4.1

Macrolides

37.3

6.9

Metronidazole

60.1

6.5

Monobactams

6.0

1.0

Oxazolidinones

6.7

0.8

Penicillins

16.5

4.1

Polymyxins

0.6

0.04

Sulfonamides

9.2

1.5

Tetracyclines

18.3

2.6

128.5

19.7

4.9

0.6

220.0

25.3

Third- and fourth-generation cephalosporins
Other
Spectrum of activity category
Anti–Bacteroides fragilisa
Anti–Clostridioides difficilea

23.2

2.9

Anti-MRSAa

161.0

23.9

Anti–Pseudomonas sppa

244.8

28.5

Abbreviations: DOT, days of therapy; MDRGN, multidrug-resistant gram-negative organism; MRSA, methicillin-resistant Staphylococcus aureus; PD, patient-days.
a

See Supplementary Appendix A for lists of agents in each spectrum of activity category.

use in teaching and nonteaching hospitals was 834 (SD, 200)
and 957 (SD, 200) DOT per 1000 PD, respectively (P < .001)
(Supplementary Figure 2).
Relationship Between Antibiotic Use and Hospital, Case-mix, and
Geographic Characteristics

Based upon the preceding results and clinical importance, we
selected 7 antibiotic groups to evaluate for usage differences
by hospital characteristics, including geographic and case-mix
distributions: all antibiotics (total), β-lactam/β-lactamase inhibitor combinations, third- and fourth-generation cephalosporins, glycopeptides, carbapenems, antipseudomonal agents,
and anti-MRSA agents. Evaluated variables are listed in Table 3.
In univariable analyses, many characteristics were associated
with antibiotic use across some or all antibiotic groups. At an
α level of .10, teaching hospitals were associated with lower use
across every antibiotic category (IRR range, 0.80–0.95). Only
1 variable, a hospital’s percentage of bacterial infection PD,
was significantly associated with antibiotic use at an α level of
P < .05 for all antibiotic groups (IRR range, where each unit
increase represents a 10 percentage-point increase in bacterial infection patient-days, 1.26–1.50; all P values < .001).
A facility’s percentage of ICU patient-days was not associated
with total antibiotic use (IRR, 1.001 [95% CI, .998–1.003];
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P = .51), but was associated with higher use of β-lactam/βlactamase inhibitor combinations, glycopeptides, carbapenems,
and antipseudomonal and anti-MRSA agents (IRR range,
1.004–1.011; all P values < .03). Unadjusted use also varied
by geographic location and antibiotic category (Figure 2 and
Supplementary Figure 3).
Variables included in adjusted models varied by antibiotic outcome, based upon significance at a P value of < .10 in univariable
analysis. In adjusted analyses, teaching status remained independently associated with lower use of third- and fourth-generation
cephalosporins and antipseudomonal agents (adjusted IRRs, 0.91
[95% CI, .85–.98], P = .016 and 0.92 [95% CI, .86–.97], P = .002, respectively) (Table 3). For the other antibiotic outcomes, including
total use, teaching status was not significant. Regional differences
also persisted in adjusted models. Compared to the South Atlantic
(chosen as the reference category because it had the largest representation in the cohort), rates of total antibiotic use were 6%,
15%, and 18% lower on average in the Pacific, New England, and
the Middle Atlantic, respectively. Carbapenems reflected the most
geographic variability, with significantly lower use in 4 divisions
(Middle Atlantic, Mountain, New England, and the Pacific) and
significantly higher use in the East South Central and the West
South Central regions. Third- and fourth-generation cephalosporins reflected no significant geographic variability (Table 3).

Days of Therapy per 1000 Patient-Days
0

50

100

150

200

250

β-lactam/β-lactamase Inhibitor Combinations
Third/Fourth-Generation Cephalosporins
Glycopeptides
First/Second-Generation Cephalosporins
Fluoroquinolones
Metronidazole
Carbapenems

Antibiotic Class

Lincosamides
Macrolides
Tetracyclines
Penicillins

Top 10 Antibiotics by DOT:

Aminoglycosides

VANCOMYCIN*

7 254 557

Sulfonamides

PIPERACILLIN/
TAZOBACTAM

5 899 822

Oxazolidinones
Monobactams
Other
Polymixins
β-lactam/β-lactamase Inhibitor Combinations for MDRGNs

Any Route

Oral

Parenteral

CEFTRIAXONE

5 514 397

CEFAZOLIN

4 253 832

LEVOFLOXACIN

3 198 914

METRONIDAZOLE

3 018 868

AZITHROMYCIN

2 343 827

CEFEPIME

2 213 722

CIPROFLOXACIN

1 516 967

MEROPENEM

1 453 809

Figure 1. Inpatient antibiotic days of therapy (DOT) per 1000 patient-days, by antibiotic class and administration route for selected agents. *Vancomycin routes of administration, by DOT: parenteral, 6 555 702; oral, 627 706; miscellaneous, 71 149. “Miscellaneous” routes of administration could not be further delineated. Abbreviations: DOT,
days of therapy; MDRGN, multidrug-resistant gram-negative organism.

DISCUSSION

To our knowledge, this is the largest study to date of US
adult inpatient antibiotic use with respect to number of
included facilities. Across 576 hospitals and nearly 12 million encounters, we found that antibiotics were used in
65% of adult hospitalizations, at a crude rate of 870 DOT
for every 1000 PD. The most commonly used classes were
β-lactam/β-lactamase inhibitor combinations, third- and
fourth-generation cephalosporins, and glycopeptides. By
spectrum of activity, the most commonly used antibiotics
were antipseudomonal agents.
Total rates of antibiotic use in this 2016–2017 inpatient population were similar to some, but not all, previously published
estimates. A 2011 survey of 70 academic hospitals (2009 data)
found similar percentages of adult encounters receiving antibiotics, 63.7%, and a hospital mean usage rate of 840 DOT/1000
PD [3]. Our hospital mean rate was considerably higher—921
DOT/1000 PD—although when restricting to teaching hospitals the rates became similar (834 DOT/1000 PD). Another
survey of approximately 300 hospitals by Baggs et al estimated a similar rate of antibiotic use in 2012 for patients aged

18–44 years, but its estimates for older patients were lower, particularly among those aged 45–64 years (850 vs 943 DOT per
1000 PD, respectively) [2]. Methodological differences limit direct comparisons, and differences in facility composition could
explain some of these discrepancies. On balance though, because teaching hospitals were associated with lower use in both
cohorts, our higher percentage of teaching hospitals (30% vs
23.2%) should have lowered our usage rates in comparison, not
raised them. Thus, while we cannot conclusively determine that
antibiotic use has increased since 2012, the data do not suggest
that it has decreased—a finding paralleled in prior conclusions
that US inpatient antibiotic use also did not significantly decrease between 2006 and 2012 [2].
Given well-publicized data that a high proportion of inpatient antibiotics are prescribed inappropriately [8, 9] and recent years’ increased emphasis on antibiotic stewardship [1, 10,
16], we were surprised that our total usage rate was similar to,
and in some cases higher than, estimates from 5–8 years prior.
Additional study results highlight at least 2 possible reasons
for these findings. First, some evidence suggests that reductions in the use of certain agents are being offset by increases
Antibiotic Use Across 576 US Hospitals • cid 2021:73 (15 July) • 217

All Antibiotics

DOT per 1000 Patient-Days

700-775

BL/BLI Combinations

127.625 - 149.569
214.316 - 219.528

199.389 - 200.238
224.636 - 263.233

Glycopeptides

99.6972 - 103.1299
113.1878 - 115.8830

110.9265 - 112.6980
119.7407 - 130.3155

776-850

851-925

926-1000

3rd/4th Gen. Cephalosporins

109.245 - 115.358
132.817 - 134.747

122.633 - 124.380
135.824 - 150.494

Carbapenems

22.3608 - 34.6537
53.3891 - 55.5248

47.5994 - 48.7843
55.7705 - 95.3897

Figure 2. Days of therapy per 1000 patient-days for selected antibiotic classes, by United States census division, 2016–2017. Abbreviations: BL/BLI, β-lactam/β-lactamase
inhibitor; DOT, days of therapy.

elsewhere. For example, the same study by Baggs et al found
that fluoroquinolones were the most commonly used antibiotics
in 2012, but their use had declined significantly since 2006,
whereas gram-negative broad-spectrum agent use increased [2].
International settings, including England and Australia, have
documented similarly stable or increased total antibiotic use
218 • cid 2021:73 (15 July) • Goodman et al

despite reductions in certain classes such as fluoroquinolones,
due to counterbalancing increases of other agents [17, 18].
Consistent with these trends, β-lactam/β-lactamase inhibitor
combinations and third- and fourth-generation cephalosporins
were the 2 highest-used classes in our 2016–2017 data, with
fluoroquinolones dropping to fifth. The fluoroquinolone rate
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1.00 (.99–1.01)

Urban

Bed sizea

0.96 (.92–1.01)
0.92 (.73–1.17)

   60 to < 70

  ≥ 70
1.89 (1.47–2.42)*
1.12 (1.02–1.22)*
1.11 (1.01–1.23)*

  < 50

   50 to < 60

   60 to < 70

Hospital CMI

0.95 (.91–.99)*

   50 to < 60

1.09 (.86–1.39)

0.95 (.74–1.21)

2.36 (1.25–4.45)*

0.69 (.40–1.20)

0.92 (.82–1.03)

0.96 (.86–1.08)

1.24 (.87–1.76)

0.97 (.62–1.53)

0.95 (.79–1.16)

0.85 (.75–.98)*

0.96 (.88–1.04)

Ref

1.32 (.85–2.06)

1.009 (1.004–1.013)*

1.47 (1.36–1.59)*

Ref

0.98 (.86–1.10)

0.90 (.78–1.03)

1.00 (.97–1.04)

Ref

0.94 (.79–1.11)

NA

1.33 (1.29–1.38)*

  < 50

Hospital mean Elixhauser
comorbidity index scoree

Age-stratified effectsd

≥ 70

60 to < 70

50 to < 60

< 50

Mean hospital patient age, yc

Percentage of PD in ICUs

Percentage of PD with a bacterial
infection diagnosisb

Ref

1.04 (.99–1.10)

South Atlantic

West South Central

0.86 (.77–.97)*

0.94 (.89–.98)
0.98 (.93–1.04)

Pacific

1.07 (.88–1.29)
0.68 (.54–.86)*

0.97 (.90–1.05)
0.85 (.77–.93)*

Mountain

New England

West North Central

0.74 (.65–.84)*

0.82 (.77–.86)*

Middle Atlantic

0.94 (.81–1.10)

0.98 (.94–1.03)
0.99 (.93–1.06)

East North Central

0.96 (.86–1.06)

NA

NA

0.97 (.89–1.06)

BL/BLIs

East South Central

US census division

0.99 (.95–1.02)
0.99 (.96–1.03)

Teaching hospital

Facility characteristic

All

1.09 (.90–1.32)

1.32 (1.15–1.51)*

2.16 (1.41–3.31)*

1.39 (.87–2.21)

1.12 (1.03–1.23)*

1.04 (.96–1.13)

1.18 (.91–1.53)

0.80 (.55–1.17)

0.95 (.89–1.01)

Ref

1.22 (.86–1.74)

NA

1.49 (1.40–1.59)*

Ref

0.98 (.89–1.08)

1.00 (.89–1.11)

1.06 (.97–1.16)

1.10 (.91–1.32)

0.90 (.77–1.04)

0.93 (.84–1.03)

0.97 (.86–1.09)

1.01 (.93–1.10)

0.99 (.97–1.02)

0.93 (.87–.99)*

0.92 (.85–.98)*

3rd/4th-Generation
Cephalosporins

1.71 (1.45–2.02)*

1.72 (1.49–2.00)*

3.71 (2.45–5.62)*

0.87 (.58–1.31)

1.00 (.92–1.08)

0.95 (.88–1.02)

1.52 (1.20–1.92)*

0.87 (.63–1.20)

0.97 (.92–1.03)

Ref

1.65 (1.21–2.24)*

1.003 (1.000–1.007)*

1.45 (1.37–1.53)*

Ref

0.99 (.91–1.07)

0.97 (.88–1.07)

0.91 (.83–.98)*

0.96 (.82–1.13)

0.92 (.81–1.05)

0.95 (.87–1.03)

0.97 (.88–1.08)

1.03 (.96–1.10)

NA

NA

0.98 (.92–1.04)

Glycopeptides

Antibiotic Category (n = 576)

Association Between Hospital, Case-mix, and Geographic Characteristics and Antibiotic Days of Therapy in Adjusted Models

Characteristic

Table 3.

0.98 (.91–1.06)
0.80 (.55–1.17)

f
f

1.66 (1.15–2.42)*

1.58 (1.07–2.33)*

0.99 (.84–1.17)

1.25 (1.10–1.42)*

2.63 (1.77–3.93)*

0.91 (.85–.98)*

6.10 (2.60–14.31)*

0.91 (.73–1.14)
f

1.06 (.78–1.43)

1.00 (.94–1.05)

Ref

1.18 (.89–1.57)

1.005 (1.002–1.008)*

1.51 (1.43–1.59)*

Ref

1.07 (.98–1.16)

0.99 (.90–1.09)

0.82 (.76–.89)*

0.69 (.59–.81)*

0.89 (.79–1.01)

0.82 (.75–.89)*

0.96 (.87–1.07)

0.98 (.92–1.05)

1.03 (1.01–1.04)*

0.97 (.92–1.03)

0.91 (.86–.97)*

Anti-PSA Agents

f

0.88 (.60–1.29)

0.95 (.84–1.07)

Ref

1.15 (.76–1.75)

1.006 (.998–1.013)

1.66 (1.47–1.88)*

Ref

1.64 (1.36–1.98)*

1.04 (.84–1.29)

0.80 (.67–.97)*

0.41 (.29–.59)*

0.48 (.36–.64)*

0.81 (.67–.99)*

1.28 (1.02–1.62)*

1.03 (.88–1.21)

NA

NA

1.03 (.90–1.17)

Carbapenems

1.37 (1.21–1.56)*

1.34 (1.20–1.51)*

2.97 (2.13–4.14)*

0.75 (.54–1.05)

1.02 (.96–1.08)

0.99 (.93–1.05)

0.99 (.83–1.18)

0.94 (.72–1.22)

0.96 (.91–1.00)

Ref

1.13 (.90–1.43)

1.002 (.999–1.004)

1.36 (1.30–1.41)*

Ref

0.99 (.92–1.06)

0.93 (.86–.99)*

0.90 (.84–.96)*

0.92 (.80–1.05)

0.91 (.82–1.01)

0.82 (.76–.88)*

1.03 (.95–1.12)

0.95 (.90–1.01)

NA

NA

1.04 (.99–1.09)

Anti-MRSA Agents

*Significant at an α level of P < .05 (and bolded).

f
Carbapenems were the sole outcome where unadjusted analyses did not support an interaction between mean Elixhauser score and average patient age; thus, mean Elixhauser score was not age-stratified in the final adjusted model for carbapenem use.
The aIRR for mean Elixhauser score in the adjusted carbapenem model was 0.83 (95% confidence interval, .73–.94; P = .004).

e
Elixhauser comorbidity categories were modified to include primary diagnoses, in addition to secondary diagnoses. Elixhauser scores represent unweighted Elixhauser comorbidity sums (1 point per comorbidity). An average patient Elixhauser score was
calculated for each hospital.

d
Biologically plausible interactions were retained in final multivariable models if at least 1 age strata’s P value was < .10 and at least 1 other strata’s P value was ≥ .10, or if effect estimates across age strata differed by > 10% in analyses including only
the main and interaction effects. Each aIRR estimate reflects the adjusted average effect of a 1-unit increase in a given variable (CMI or mean Elixhauser comorbidity index score) in hospitals with this average patient age, holding other factors constant.

Hospital mean patient age was stratified into 4 categories to increase interpretability of interactions by age (mean Elixhauser score and CMI). aIRR estimates for each age strata reflect the adjusted effect of age, relative to the reference category of 50 to
< 60 years, at the cohort’s mean Elixhauser score and mean CMI values (3.2 and 1.49, respectively).

c

Agency for Healthcare Research and Quality (AHRQ) bacterial infection diagnosis codes were used to ascertain whether a patient’s primary International Classification of Diseases, Tenth Revision diagnosis was infection-related (AHRQ, 2019). Inpatient-days
for encounters with a primary infection diagnosis were treated as “bacterial infection” patient-days. Each adjusted incidence rate ratio (aIRR) represents the average effect of a 10 percentage point increase in a hospital’s percentage of bacterial infection
patient-days, holding other factors constant.

Bed size was coded ordinally, categories 1–6. Each 1-unit increase represents an additional 100 beds, up to ≥ 500 (reference ≤ 99 beds).

b

a

Abbreviations: anti-MRSA, agents with targeted activity against methicillin-resistant Staphylococcus aureus; anti-PSA, agents with targeted activity against Pseudomonas spp; BL/BLI, β-lactam/β-lactamase inhibitor combination; CMI, case-mix index; ICU,
intensive care unit; NA, variable was not included in a given model because in unadjusted analysis its P value was ≥ .10; PD, patient-days; US, United States.

1.63 (1.23–2.17)*
1.47 (1.02–2.10)*
2.03 (.88–4.72)
1.94 (1.35–2.80)*
1.15 (.78–1.68)
1.66 (.96–2.87)
1.25 (1.01–1.56)*
  ≥ 70

Data are presented as adjusted incidence rate ratio (95% confidence interval). Associations were evaluated using multivariable negative binomial regression models with an offset equal to the natural log of total patient-days per facility. Included variables
varied by antibiotic outcome.

Anti-MRSA Agents
Anti-PSA Agents
Carbapenems
Glycopeptides
Characteristic

All

BL/BLIs

3rd/4th-Generation
Cephalosporins

Antibiotic Category (n = 576)

Continued
Table 3.
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per 1000 PD (75 DOT) was also well below the 2012 estimate
(117 DOT), even though the latter included pediatric patients
[2]. Viewed in isolation, the reduction in fluoroquinolone use is
encouraging [4, 19–23]. Globally, however, the relative increase
in other broad-spectrum agents—and, at best, no apparent reduction in total antibiotic use—is concerning and underscores
the importance of performing stewardship across all antibiotic
classes, not just select broad-spectrum agents.
Second, it is possible that antibiotic stewardship programs
(ASPs) are reducing total antibiotic use—but their uptake remains
too limited across US facilities to drive national reductions. As
noted previously, teaching hospitals averaged significantly less total
antibiotic use (834 vs 957 DOT/1000 PD; P < .001). In adjusted
analyses, teaching status also remained independently associated
with lower use of third- and fourth-generation cephalosporins
and antipseudomonal agents; nowhere was it associated with
higher use. These findings are consistent with other studies [2,
24], and we hypothesize that teaching status may be a surrogate
for well-established ASPs [10, 25–27], which are more common in
teaching hospitals [28, 29]. As of 2015, however, only 48% of respondent US hospitals in an NHSN survey had implemented ASPs
incorporating the “7 CDC Core Elements” [29]. Promisingly, ASP
uptake is increasing [28–30], and CMS recently finalized regulations requiring ASPs in all acute care hospitals that participate in
Medicare/Medicaid [31]. We hope that these regulatory changes
will spur the development and refinement of ASPs, leading to further reductions in unnecessary antibiotic prescribing.
We documented significant regional differences in antibiotic use, even after controlling for many hospital and case-mix
characteristics. For many antibiotic groups, adjusted usage rates
were significantly lower in the Middle Atlantic, the Pacific, and
New England, compared to the South Atlantic. For example,
hospitals’ average use of antipseudomonal agents was 18%, 18%,
and 31% lower in these respective divisions. The high use of
antipseudomonal antibiotics in our study (245 DOT/1000 PD),
coupled with intensifying concerns about multidrug-resistant
Pseudomonas aeruginosa [32–35], make better understanding
the reasons for these regional differences critical. We also compared antibiotic use to regional antimicrobial resistance using
2014 NHSN healthcare-acquired infection (HAI) data but only
identified partial concordance. For example, while the East
South Central had the highest proportion of MRSA isolates and
the highest use of anti-MRSA agents, there were also notable
discrepancies (eg, high use in the Mountain division despite
low proportions of MRSA isolates) [36]. Interestingly, there was
strong overlap between high inpatient usage regions and high
outpatient usage regions using publicly available data from the
same time period. In our cohort, by crude usage rate the East
South Central and the West South Central regions were consistently in the “top 3,” including for total antibiotics, carbapenems,
and antipseudomonal and anti-MRSA agents. Six of the 7 states
with the highest rates of community antibiotic prescriptions in

2016 also fall in these regions [37]. These findings reinforce the
importance of antibiotic stewardship at all points on the healthcare continuum, and further study may uncover shared reasons
for high utilization in inpatient and outpatient settings.
Our study has several limitations. First, our study did not
include pediatric patients. Continued exploration of antibiotic utilization in pediatric populations is an important area
for future study. Second, because our cohort lacked microbiology data, we were unable to compare antibiotic usage and
antimicrobial resistance directly. In the alternative, we crossreferenced usage to NHSN regional resistance data, but we
recognize that causal inferences are limited by these ecologic
comparisons. More directly correlating use and resistance
would be important, including from other facility and nonHAI data sources. Third, although our database includes a
large and diverse number of hospitals across the US, we did
not explicitly weight our estimates to reflect national distributions, and some facility types may have been overrepresented.
Nevertheless, our study population included nearly 25% of
hospitals located in rural locations and/or possessing < 100
beds, and we reported stratified rates where informative (eg,
by teaching status). Our adjusted models also controlled for
many facility characteristics. Finally, our study used administrative claims data, which may have misclassified some information, although this is a recognized limitation of most
similar surveys [2, 3, 38]. However, we would not expect
any misclassification to be differential. Moreover, although a
study of this size and geographic distribution would not have
been feasible without a centralized repository of electronic
claims data, these data did not include certain variables (eg,
ASP presence, percentage of encounters with infectious disease consultations) that might further explain observed
utilization differences. We hope that our research identifies
important targets for follow-up study.
Overall, we found that in a large, diverse cohort of US hospitals, adult inpatients had high rates of antibiotic use, driven predominantly by broad-spectrum agents. Our results suggest that
total antibiotic use has not decreased when compared to earlier
studies. Teaching hospitals had lower rates of total antibiotic use,
and lower use of third- and fourth-generation cephalosporins and
antipseudomonal agents in adjusted models. Teaching status may
be a surrogate for facilities that are more likely to have robust ASPs,
but further testing of this hypothesis is needed. Even accounting
for teaching status and many other facility characteristics, there remained significant regional differences in antibiotic use that geographic patterns of resistance do not appear to explain fully. Better
understanding other reasons for these differences may inform efforts to optimize antibiotic use.
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